Zhang Zhe, Jin Zeping, Yang Xiaojie, Zhang Liang, Zhang Yang, Liu Dayuan, Chi Xiaohan, Hao Shuyu, Feng Jie, Ji Nan
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
National Clinical Research Center for Neurological Diseases (China), Beijing, China.
Front Neurol. 2020 Dec 8;11:591615. doi: 10.3389/fneur.2020.591615. eCollection 2020.
Neuropsychological deficits frequently occur in diffuse lower-grade glioma (DLGG) patients, but their relationship with molecular subgroups based on the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) is unclear. All patients enrolled for this study were divided into different subgroups according to the molecular-integrated 2016 CNS WHO and morphology-centric 2007 CNS WHO to compare their neurocognitive function (NCF) dysfunction. Univariate and multivariate analyses were used to assess the independent factors for NCF decline. The performance of NCF changes for discrimination of IDH and 1p19q status was evaluated by receiver operating characteristic (ROC). There was no significant difference in the clinical characteristics among the molecular and morphologic subgroups. In the molecular subgroups, significant differences in NCF alterations were found in terms of attention function, working memory and executive function in grade II glioma patients; in addition to these changes in NCF, memory function and abstract thinking were also significantly different in grade III glioma patients. The pairwise comparison further confirmed that patients with astrocytoma (A)/anaplastic astrocytoma (AA) with isocitrate dehydrogenase wild-type (IDHwt) glioma were more susceptible to severe cognitive decline in terms of the NCF performance described above. For the morphologic subgroups, only working memory was significantly different in grade III glioma patients. The distribution proportion was significantly different among each subgroup of DLGG (grade II, = 0.001; grade III, = 0.002). The proportion of extensive NCF decline (≥5 tests) was 4, 12, and 50% in the IDH mutant oligodendroglioma (IDHm-O), IDHm-A, and IDHwt-A subgroups, and this proportion was 33, 60, and 93% in the IDHm-AO, IDHm-AA, and IDHwt-AA subgroups, respectively. In multivariate regression analysis, molecular types were independent factors for NCF alterations after adjusted the factors of tumor and demographics ( < 0.05). ROC curves suggested combined NCF tests model showed an advantage in the differentiation of IDH status. NCF alteration is closely related to molecular-integrated subgroups with varying degrees and frequencies in DLGG. Patients with IDHwt gliomas are more susceptible to suffer from severe and extensive NCF decline than other subgroups.
神经心理学缺陷在弥漫性低级别胶质瘤(DLGG)患者中经常出现,但它们与基于2016年世界卫生组织(WHO)中枢神经系统(CNS)肿瘤分类的分子亚组之间的关系尚不清楚。本研究纳入的所有患者根据2016年CNS WHO分子整合分类和以形态学为中心的2007年CNS WHO分类分为不同亚组,以比较他们的神经认知功能(NCF)障碍。采用单因素和多因素分析评估NCF下降的独立因素。通过受试者操作特征(ROC)曲线评估NCF变化对异柠檬酸脱氢酶(IDH)和1p19q状态的鉴别性能。分子和形态学亚组之间的临床特征无显著差异。在分子亚组中,II级胶质瘤患者在注意力功能、工作记忆和执行功能方面的NCF改变存在显著差异;除了这些NCF变化外,III级胶质瘤患者的记忆功能和抽象思维也存在显著差异。两两比较进一步证实,具有异柠檬酸脱氢酶野生型(IDHwt)胶质瘤的星形细胞瘤(A)/间变性星形细胞瘤(AA)患者在上述NCF表现方面更容易出现严重的认知下降。对于形态学亚组,只有III级胶质瘤患者的工作记忆存在显著差异。DLGG各亚组之间的分布比例存在显著差异(II级, = 0.001;III级, = 0.002)。IDH突变型少突胶质细胞瘤(IDHm-O)、IDHm-A和IDHwt-A亚组中广泛NCF下降(≥5项测试)的比例分别为4%、12%和50%,而在IDHm-AO、IDHm-AA和IDHwt-AA亚组中,这一比例分别为33%、60%和93%。在多因素回归分析中,调整肿瘤和人口统计学因素后,分子类型是NCF改变的独立因素( < 0.05)。ROC曲线表明,联合NCF测试模型在鉴别IDH状态方面具有优势。在DLGG中,NCF改变与分子整合亚组在不同程度和频率上密切相关。与其他亚组相比,IDHwt胶质瘤患者更容易出现严重和广泛的NCF下降。